Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Status:
Completed
Trial end date:
2018-11-13
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to
evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of
different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a)
[Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular
disease (CVD).